HIV-associated Kaposi sarcoma: Pathogenesis and therapy;HIV-assoziiertes Kaposi-sarkom, pathogenese und therapie

JDDG - Journal of the German Society of Dermatology

Volumn 5, Issue 12, 2007, Pages 1091-1094

  Potthoff, Anja ^a   Brockmeyer, Norbert H ^a,b  

^a ST JOSEF HOSPITAL   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Angiogenesis; Cytokine receptors; Growth factor; Interferon; Metalloproteinase; Tumor progression

Indexed keywords

ALITRETINOIN; ALPHA INTERFERON; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BORTEZOMIB; CD4 ANTIGEN; CYCLIN D2; DOXORUBICIN; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 2; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; PROTEIN BCL 2; RAPAMYCIN; SORAFENIB; VASCULOTROPIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; CRYOSURGERY; DIAGNOSTIC APPROACH ROUTE; DRUG TOLERABILITY; HAND FOOT SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; KAPOSI SARCOMA; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; PATHOGENESIS; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; HERPESVIRUS 8, HUMAN; HUMANS; RISK FACTORS; SARCOMA, KAPOSI; SKIN NEOPLASMS; VIRULENCE;

EID: 36949026136     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2007.06567.x     Document Type: Review

References (25)

1. Kaposi M. Idiopathisches multiples Pigmentsarkom der Haut. Arch Derm Syph 1872 4 : 265 273.
2. Campistol JM, Schena FP. Kaposi's sarcoma in renal transplant recipients - the impact of proliferation signal inhibitors. Nephrol Dial Transplant 2007 22 Suppl 1 : 17 22.
3. CDC. Kaposi's sarcoma and pneumocystis pneumonia among homosexual men - New York City and California. MMWR 1981 30 : 305 308.
4. Rezza G, Adreoni M, Dorrucci M, Pezzetti P, Monini P, Zerbini R, Salassa B, Colangeli V, Sarmati L, Nicastri E, Barbanera M, Pristera R, Aiuti F, Ortona L, Ensoli B. Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases. J Natl Cancer Inst 1999 91 : 1468 1474.
5. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J Knowles DM, Moore PS. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994 266 : 1865 1869.
6. Neipel F, Albrecht JC, Fleckenstein B. Human herpesvirus 8 - the first human rhadinovirus. JNCI Monographs 1998 23 : 73 77.
7. Sullivan R, Dezube BJ, Koon HB. Signal transduction targets in Kaposi's sarcoma. Curr Opin Oncol 2007 18 : 456 462.
8. Aoki Y, Tosato G. Targeted inhibition of angiogenic factors in AIDS-related disorders. Curr Drug Targets Infect Disord 2003 3 : 115 128.
9. Brockmeyer NH, Barthel B. Clinical manifestations and therapies of AIDS associated tumors. Eur J Med Res. 1998 3 : 127 147.
10. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1989 7 : 1201 1207.
11. Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, Palladino C, Leone P, Bugarini R, Malavasi L, Cafaro A, Falchi M, Valdembri D, Rezza G, Bussoloino F, Monini P, Ensoli B. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi's sarcoma. Nat Med 2002 8 : 225 232.
12. Leidner RS, Aboulafia DM. Recrudescent Kaposi's sarcoma after initiation of HAART-a manifestation of immune reconstitution syndrome. AIDS Patient Care STDs 2005 19 : 635 644.
13. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003 348 : 1681 1691.
14. Kreuter A, Rasokat H, Klouche M, Esser S, Bader A, Gambichler T, Altmeyer P, Brockmeyer NH. Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers. Cancer Invest 2005 23 : 653 659.
15. Dt. Krebsgesellschaft. Kurzgefasste Interdisziplinäre Leitlinien Kaposi-Sarkom 2002 3 : 1 12.
16. Morganroth GS. Topical 0.1% alitretinoin gel for classic Kaposi sarcoma. Arch Dermatol 2002 138 : 542 543.
17. Schöfer H, Ochsendorf FR, Hochscheid I, Mulbradt R. Kaposi-Sarkome im Gesicht: Palliative Behandlung mit Kryochirurgie, intraläsionaler Chemotherapie, Röntgenweichstrahltherapie und Camouflage. Hautarzt 1991 42 : 492 498.
18. Stelzer KJ, Griffin TW. A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma. Int J Radiat Oncol Biol Phys. 1993 27 : 1057 1061.
19. Krown SE, Li P, Von Roenn JH, Paredes J, Huang J, Testa MA. Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study. J Interferon Cytokine Res 2002 22 : 295 303.
20. Rasokat H, Haussermann L, Minnemann M. Response of AIDS-related Kaposi's sarcoma to treatment with recombinant interferon alpha depends on the stage of underlying immunodeficiency. J Invest Dermatol 1989 89 : 444 445.
21. Cooley T, Henry D, Tonda M, Sun S, O'Connel M, Rackoff W. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. Oncologist 2007 12 : 114 123.
22. Tulpule A, Groopman J, Saville MW, Harrington W Jr., Friedman-Kien A, Espina BM, Garces C, Mantelle L, Mettinger K, Scadden DT, Gill PS. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi's sarcoma. Cancer 2002 95 : 147 154.
23. Sullivan R, Dezube BJ, Koon HB. Signal transduction targets in Kaposi's sarcoma. Curr Opin Oncol 2007 18 : 456 462.
24. Koon HB, Bubley GJ, Pantanowitz L, Masiello D, Smith B, Crosby K, Proper J, Weeden W, Miller TE, Chatis P, Egorin MJ, Tahan SR, Dezube BJ. Imatinib- induced regression of AIDS-related Kapos's sarcoma. J Clin Oncol 2005 23 : 982 989.
25. Dezube BJ, Krown SE, Lee JY, Bauer KS, Aboulafia DM. Randomized Phase II Trial of matrix metalloproteiase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: An AIDS malignancy consortium study. J Clin Oncol 24 : 1389 1394.